Table 1.
Clinical characteristics of patients according to IL‐37 in the training and validation cohorts
| Variables | Training cohort (n = 337) | Validation cohort (n = 245) | ||||||
|---|---|---|---|---|---|---|---|---|
| N | Low IL‐37 (%) | High IL‐37 (%) | P value | N | Low IL‐37 (%) | High IL‐37 (%) | P value | |
| Gender | ||||||||
| Male | 208 | 105 (50.5%) | 103 (49.5%) | 0.877 | 145 | 77 (53.1%) | 68 (46.9%) | 0.212 |
| Female | 129 | 64 (49.6%) | 65 (50.4%) | 100 | 45 (45.0%) | 55 (55.0%) | ||
| Age (y) | ||||||||
| <60 | 176 | 91 (51.7%) | 85 (48.3%) | 0.55 | 125 | 61 (48.8%) | 64 (51.2%) | 0.75 |
| ≧60 | 161 | 78 (48.4%) | 83 (51.6%) | 120 | 61 (50.8%) | 59 (49.2%) | ||
| Tumor location | ||||||||
| Colon | 155 | 80 (51.6%) | 75 (48.4%) | 0.62 | 108 | 54 (50.0%) | 54 (50.0%) | 0.955 |
| Rectum | 182 | 89 (48.9%) | 93 (51.1%) | 137 | 68 (49.6%) | 69 (50.4%) | ||
| Differentiation status | ||||||||
| Well | 153 | 80 (52.3%) | 73 (47.7%) | 0.77 | 150 | 81 (54.0%) | 69 (46.0%) | 0.247 |
| Moderate | 140 | 68 (48.6%) | 72 (51.4%) | 73 | 31 (42.5%) | 42 (57.5%) | ||
| Poor and undifferentiated | 44 | 21 (47.7%) | 23 (52.3%) | 22 | 10 (45.5%) | 12 (54.5%) | ||
| CEA | ||||||||
| Elevated | 103 | 60 (58.3%) | 43 (41.7%) | 0.048 | 71 | 43 (60.6%) | 28 (39.4%) | 0.031 |
| Normal | 234 | 109 (46.6%) | 125 (53.4%) | 174 | 79 (45.4%) | 95 (54.6%) | ||
| CA199 | ||||||||
| Elevated | 58 | 27 (50.9%) | 31 (49.1%) | 0.547 | 42 | 26 (61.9%) | 16 (38.1%) | 0.085 |
| Normal | 279 | 142 (46.6%) | 137 (53.4%) | 203 | 96 (48.4%) | 107 (51.6%) | ||
| Depth of invasion | ||||||||
| T1 | 16 | 4 (25%) | 12 (75%) | 0.011 | 14 | 6 (42.9%) | 8 (57.1%) | 0.104 |
| T2 | 46 | 20 (43.5%) | 26 (56.5%) | 45 | 18 (40.0%) | 27 (60.0%) | ||
| T3 | 206 | 99 (48.1%) | 107 (51.9%) | 118 | 55 (46.6%) | 63 (53.4%) | ||
| T4a | 15 | 11 (73.3%) | 4 (26.7%) | 19 | 11 (57.9%) | 8 (42.1%) | ||
| T4b | 54 | 35 (64.8%) | 19 (35.2%) | 49 | 32 (57.1%) | 17 (42.9%) | ||
| Lymph node metastasis | ||||||||
| N0 | 197 | 88 (44.7%) | 109 (55.3%) | 0.041 | 132 | 54 (40.9%) | 78 (59.1%) | 0.003 |
| N1 | 99 | 55 (55.6%) | 44 (44.4%) | 78 | 43 (55.1%) | 35 (44.9%) | ||
| N2 | 41 | 26 (63.4%) | 15 (36.6%) | 35 | 25 (71.4%) | 10 (28.6%) | ||
| Metastasis | ||||||||
| M0 | 298 | 142 (47.7%) | 156 (52.3%) | 0.011 | 215 | 99 (46.0%) | 116 (54.0%) | 0.002 |
| M1 | 39 | 27 (69.2%) | 12 (30.8%) | 30 | 23 (67.4%) | 7 (32.6%) | ||
| TNM stage | ||||||||
| I | 52 | 20 (38.5%) | 32 (61.5%) | 0.023 | 42 | 14 (33.3%) | 28 (66.7%) | 0.001 |
| II | 133 | 62 (46.6%) | 71 (53.4%) | 82 | 34 (41.5%) | 48 (58.5%) | ||
| III | 113 | 60 (53.1%) | 53 (46.9%) | 91 | 51 (56.0%) | 40 (44.0%) | ||
| IV | 39 | 27 (69.2%) | 12 (30.8%) | 30 | 23 (76.7%) | 7 (23.3%) | ||
| CD66b cells/field (mean±SD) | 70.1 ± 45.2 | 57.6 ± 34.2 | 0.004 | 65.5 ± 38.2 | 51.3 ± 34.1 | 0.003 | ||
| CD66b | ||||||||
| Low | 169 | 75 (44.4%) | 94 (55.6%) | 0.034 | 123 | 46 (37.4%) | 77 (62.6%) | <0.0001 |
| High | 168 | 94 (56.0%) | 74 (44.0%) | 122 | 76 (62.3%) | 46 (37.7%) | ||
| MMR | ||||||||
| dMMR | 63 | 19 (30.2%) | 44 (69.8%) | 0.0004 | 46 | 21 (45.7%) | 25 (54.3%) | 0.533 |
| pMMR | 274 | 150 (54.7%) | 124 (45.3%) | 199 | 101 (50.8%) | 98 (49.2%) | ||